1. Neutropenia in Incarcerated Adolescents Secondary to Intranasal Quetiapine Misuse
- Author
-
Leigh Haysom, Donna Blomgren, MClin Epi, John Kasinathan, and Jacqueline Canessa
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Neutropenia ,Adolescent ,Prescription Drug Diversion ,business.industry ,Prisoners ,medicine.disease ,Psychiatry and Mental health ,Quetiapine Fumarate ,Pediatrics, Perinatology and Child Health ,medicine ,Quetiapine ,Humans ,Pharmacology (medical) ,New South Wales ,business ,Young male ,Administration, Intranasal ,medicine.drug ,Antipsychotic Agents - Abstract
Objective: Between April 2015 and May 2016, a number of young males incarcerated at a Youth Justice center in New South Wales, Australia, were noted to have unexplained and significant neutropenia. None of the adolescents were prescribed quetiapine; however, it was prescribed for other young people in the center for this time period. The authors undertook a case series review to investigate the cause of this neutropenia. Methods: Case series review, including review of all pathology, electrocardiograms, medication charts, and medical file notes. Results: Quetiapine was used in the center; however, none of the young people with neutropenia were prescribed quetiapine (or any other medication causing neutropenia). During the assessments of these young people, it was found that the administration of quetiapine had changed during this time period to using pulverized quetiapine powder, administered after hours to young people when there were no health center staff available to supervise. On questioning, two neutropenic young people admitted to "snorting" diverted quetiapine powder. All instances of neutropenia resolved once the medication was removed from the center. Conclusions: Quetiapine has a high potential for abuse, especially in custodial settings. Quetiapine should never be crushed as this increases the potential for diversion, misuse, and serious side effects. Quetiapine misuse should be considered part of the differential diagnosis of unexplained neutropenia, especially in a setting where the drug is available.
- Published
- 2020